Differences in Retention-Related Risk Factors and Potential Resources across First-Generation and Non-First-Generation College Students

This study was completed to examine the differences in experience of first-generation and non-first-generation college students both before and during college. The purpose focused on retention-related risk factors as well as potential resources. The study was conducted through an online survey system called Qualtrics. There were 246 participants from the psychology department of the University of Nebraska- Lincoln, and participants received research credits for completing the survey. The study included measures for stress, depression symptoms, anxiety, perceived support as well as questions regarding academic practices and biographical information. The results of the study were analyzed using SPSS software, and they indicated that high-achieving first-generation and non-first-generation students do not significantly differ across many academic practices during college; however, implications do exist for first-generation college students in preparation for college as well as their attainment of social and cultural capital upon arriving on a college campus

Is the sky the limit? Performance of the revamped Swedish 1-m Solar Telescope and its blue- and red-beam re-imaging systems

We demonstrate that for data recorded with a solar telescope that uses adaptive optics and/or post-processing to compensate for many low- and high-order aberrations, the RMS granulation contrast is directly proportional to the Strehl ratio calculated from the residual (small-scale) wavefront error. We demonstrate that the wings of the high-order compensated PSF for SST are likely to extend to a radius of not more than about 2 arcsec, consistent with earlier conclusions drawn from straylight compensation of sunspot images. We report on simultaneous measurements of seeing and solar granulation contrast averaged over 2 sec time intervals at several wavelengths from 525 nm to 853.6 nm on the red-beam (CRISP beam) and wavelengths from 395 nm to 484 nm on the blue-beam (CHROMIS beam). These data were recorded with the Swedish 1-m Solar Telescope (SST) that has been revamped with an 85-electrode adaptive mirror and a new tip-tilt mirror, both of which were polished to exceptionally high optical quality. The highest 2-sec average image contrast measured in April 2015 through 0.3-0.9 nm interference filters at 525 nm, 557 nm, 630 nm and 853.5 nm with compensation only for the diffraction limited point spread function of SST is 11.8%, 11.8%, 10.2% and 7.2% respectively. Similarly, the highest 2-sec contrast measured at 395 nm, 400 nm and 484 nm in May 2016 through 0.37-1.3 nm filters is 16%, 16% and 12.5% respectively. The granulation contrast observed with SST compares favorably with that of other telescopes. Simultaneously with the above wideband red-beam data, we also recorded narrow-band continuum images with the CRISP imaging spectropolarimeter. We find that contrasts measured with CRISP are entirely consistent with the corresponding wide-band contrasts, demonstrating that any additional image degradation by the CRISP etalons and telecentric optical system is marginal or even insignificant.Comment: In press in Astronomy & Astrophysic

High-contrast Imaging from Space: Speckle Nulling in a Low Aberration Regime

High-contrast imaging from space must overcome two major noise sources to successfully detect a terrestrial planet angularly close to its parent star: photon noise from diffracted star light, and speckle noise from star light scattered by instrumentally-generated wavefront perturbation. Coronagraphs tackle only the photon noise contribution by reducing diffracted star light at the location of a planet. Speckle noise should be addressed with adaptative-optics systems. Following the tracks of Malbet, Yu and Shao (1995), we develop in this paper two analytical methods for wavefront sensing and control that aims at creating dark holes, i.e. areas of the image plane cleared out of speckles, assuming an ideal coronagraph and small aberrations. The first method, speckle field nulling, is a fast FFT-based algorithm that requires the deformable-mirror influence functions to have identical shapes. The second method, speckle energy minimization, is more general and provides the optimal deformable mirror shape via matrix inversion. With a NxN deformable mirror, the size of matrix to be inverted is either N^2xN^2 in the general case, or only NxN if influence functions can be written as the tensor product of two one-dimensional functions. Moreover, speckle energy minimization makes it possible to trade off some of the dark hole area against an improved contrast. For both methods, complex wavefront aberrations (amplitude and phase) are measured using just three images taken with the science camera (no dedicated wavefront sensing channel is used), therefore there are no non-common path errors. We assess the theoretical performance of both methods with numerical simulations, and find that these speckle nulling techniques should be able to improve the contrast by several orders of magnitude.Comment: 31 pages, 8 figures, 1 table. Accepted for publication in ApJ (should appear in February 2006

On-sky multi-wavelength phasing of segmented telescopes with the Zernike phase contrast sensor

Future Extremely Large Telescopes will adopt segmented primary mirrors with several hundreds of segments. Cophasing of the segments together is essential to reach high wavefront quality. The phasing sensor must be able to maintain very high phasing accuracy during the observations, while being able to phase segments dephased by several micrometers. The Zernike phase contrast sensor has been demonstrated on-sky at the Very Large Telescope. We present the multi-wavelength scheme that has been implemented to extend the capture range from \pmlambda/2 on the wavefront to many micrometers, demonstrating that it is successful at phasing mirrors with piston errors up to \pm4.0 micron on the wavefront. We discuss the results at different levels and conclude with a phasing strategy for a future Extremely Large Telescope.Comment: 17 pages, 8 figures, 2 tables. Accepted for publication in Applied Optics; he final publised version is available on the OSA website: http://www.opticsinfobase.org/abstract.cfm?msid=13671

Inhaled corticosteroids versus long-acting beta -agonists for chronic obstructive pulmonary disease (Review).

Long-acting beta(2)-agonists and inhaled corticosteroids can be used as maintenance therapy by patients with moderate to severe chronic obstructive pulmonary disease. These interventions are often taken together in a combination inhaler. However, the relative added value of the two individual components is unclear

On the Moat-Penumbra Relation

Proper motions in a sunspot group with a delta-configuration and close to the solar disc center have been studied by employing local correlation tracking techniques. The analysis is based on more than one hour time series of G-band images. Radial outflows with a mean speed of 0.67 km s^{-1} have been detected around the spots, the well-known sunspots moats. However, these outflows are not found in those umbral core sides without penumbra. Moreover, moat flows are only found in those sides of penumbrae located in the direction marked by the penumbral filaments. Penumbral sides perpendicular to them show no moat flow. These results strongly suggest a relation between the moat flow and the well-known, filament aligned, Evershed flow. The standard picture of a moat flow originated from a blocking of the upward propagation of heat is commented in some detail.Comment: 4 pages, 4 figures, To appear in ApJ Letter

Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease.

BACKGROUND: Inhaled corticosteroids (ICS) are anti-inflammatory drugs that have proven benefits for people with worsening symptoms of chronic obstructive pulmonary disease (COPD) and repeated exacerbations. They are commonly used as combination inhalers with long-acting beta2-agonists (LABA) to reduce exacerbation rates and all-cause mortality, and to improve lung function and quality of life. The most common combinations of ICS and LABA used in combination inhalers are fluticasone and salmeterol, budesonide and formoterol and a new formulation of fluticasone in combination with vilanterol, which is now available. ICS have been associated with increased risk of pneumonia, but the magnitude of risk and how this compares with different ICS remain unclear. Recent reviews conducted to address their safety have not compared the relative safety of these two drugs when used alone or in combination with LABA. OBJECTIVES: To assess the risk of pneumonia associated with the use of fluticasone and budesonide for COPD. SEARCH METHODS: We identified trials from the Cochrane Airways Group Specialised Register of trials (CAGR), clinicaltrials.gov, reference lists of existing systematic reviews and manufacturer websites. The most recent searches were conducted in September 2013. SELECTION CRITERIA: We included parallel-group randomised controlled trials (RCTs) of at least 12 weeks' duration. Studies were included if they compared the ICS budesonide or fluticasone versus placebo, or either ICS in combination with a LABA versus the same LABA as monotherapy for people with COPD. DATA COLLECTION AND ANALYSIS: Two review authors independently extracted study characteristics, numerical data and risk of bias information for each included study.We looked at direct comparisons of ICS versus placebo separately from comparisons of ICS/LABA versus LABA for all outcomes, and we combined these with subgroups when no important heterogeneity was noted. After assessing for transitivity, we conducted an indirect comparison to compare budesonide versus fluticasone monotherapy, but we could not do the same for the combination therapies because of systematic differences between the budesonide and fluticasone combination data sets.When appropriate, we explored the effects of ICS dose, duration of ICS therapy and baseline severity on the primary outcome. Findings of all outcomes are presented in 'Summary of findings' tables using GRADEPro. MAIN RESULTS: We found 43 studies that met the inclusion criteria, and more evidence was provided for fluticasone (26 studies; n = 21,247) than for budesonide (17 studies; n = 10,150). Evidence from the budesonide studies was more inconsistent and less precise, and the studies were shorter. The populations within studies were more often male with a mean age of around 63, mean pack-years smoked over 40 and mean predicted forced expiratory volume of one second (FEV1) less than 50%.High or uneven dropout was considered a high risk of bias in almost 40% of the trials, but conclusions for the primary outcome did not change when the trials at high risk of bias were removed in a sensitivity analysis.Fluticasone increased non-fatal serious adverse pneumonia events (requiring hospital admission) (odds ratio (OR) 1.78, 95% confidence interval (CI) 1.50 to 2.12; 18 more per 1000 treated over 18 months; high quality), and no evidence suggested that this outcome was reduced by delivering it in combination with salmeterol or vilanterol (subgroup differences: I(2) = 0%, P value 0.51), or that different doses, trial duration or baseline severity significantly affected the estimate. Budesonide also increased non-fatal serious adverse pneumonia events compared with placebo, but the effect was less precise and was based on shorter trials (OR 1.62, 95% CI 1.00 to 2.62; six more per 1000 treated over nine months; moderate quality). Some of the variation in the budesonide data could be explained by a significant difference between the two commonly used doses: 640 mcg was associated with a larger effect than 320 mcg relative to placebo (subgroup differences: I(2) = 74%, P value 0.05).An indirect comparison of budesonide versus fluticasone monotherapy revealed no significant differences with respect to serious adverse events (pneumonia-related or all-cause) or mortality. The risk of any pneumonia event (i.e. less serious cases treated in the community) was higher with fluticasone than with budesonide (OR 1.86, 95% CI 1.04 to 3.34); this was the only significant difference reported between the two drugs. However, this finding should be interpreted with caution because of possible differences in the assignment of pneumonia diagnosis, and because no trials directly compared the two drugs.No significant difference in overall mortality rates was observed between either of the inhaled steroids and the control interventions (both high-quality evidence), and pneumonia-related deaths were too rare to permit conclusions to be drawn. AUTHORS' CONCLUSIONS: Budesonide and fluticasone, delivered alone or in combination with a LABA, are associated with increased risk of serious adverse pneumonia events, but neither significantly affected mortality compared with controls. The safety concerns highlighted in this review should be balanced with recent cohort data and established randomised evidence of efficacy regarding exacerbations and quality of life. Comparison of the two drugs revealed no statistically significant difference in serious pneumonias, mortality or serious adverse events. Fluticasone was associated with higher risk of any pneumonia when compared with budesonide (i.e. less serious cases dealt with in the community), but variation in the definitions used by the respective manufacturers is a potential confounding factor in their comparison.Primary research should accurately measure pneumonia outcomes and should clarify both the definition and the method of diagnosis used, especially for new formulations such as fluticasone furoate, for which little evidence of the associated pneumonia risk is currently available. Similarly, systematic reviews and cohorts should address the reliability of assigning 'pneumonia' as an adverse event or cause of death and should determine how this affects the applicability of findings

Increase in Legionnaires' disease cases associated with travel to Dubai among travellers from the United Kingdom, Sweden and the Netherlands, October 2016 to end August 2017.

Between 1 October 2016 and 31 August 2017, 51 Legionnaires' disease (LD) cases from the United Kingdom, Sweden and the Netherlands were identified with associated travel to Dubai. Cases did not all stay in the same accommodation, indicating that no single accommodation could be the source for all these infections. While local investigations continue into other potential sources, clinicians should remain alert to the possibility of LD among travellers returning from Dubai with respiratory illness

Evaluation of phase-diversity techniques for solar-image restoration

Phase-diversity techniques provide a novel observational method for overcomming the effects of turbulence and instrument-induced aberrations in ground-based astronomy. Two implementations of phase-diversity techniques that differ with regard to noise model, estimator, optimization algorithm, method of regularization, and treatment of edge effects are described. Reconstructions of solar granulation derived by applying these two implementations to common data sets are shown to yield nearly identical images. For both implementations, reconstructions from phase-diverse speckle data (involving multiple realizations of turbulence) are shown to be superior to those derived from conventional phase-diversity data (involving a single realization). Phase-diverse speckle reconstructions are shown to achieve near diffraction-limited resolution and are validated by internal and external consistency tests, including a comparison with a reconstruction using a well-accepted speckle-imaging method

Long-acting beta2-agonists for chronic obstructive pulmonary disease.

BACKGROUND: Chronic obstructive pulmonary disease (COPD) is a respiratory disease that causes progressive symptoms of breathlessness, cough and mucus build-up. It is the fourth or fifth most common cause of death worldwide and is associated with significant healthcare costs.Inhaled long-acting beta2-agonists (LABAs) are widely prescribed to manage the symptoms of COPD when short-acting agents alone are no longer sufficient. Twice-daily treatment with an inhaled LABA is aimed at relieving symptoms, improving exercise tolerance and quality of life, slowing decline and even improving lung function and preventing and treating exacerbations. OBJECTIVES: To assess the effects of twice-daily long-acting beta2-agonists compared with placebo for patients with COPD on the basis of clinically important endpoints, primarily quality of life and COPD exacerbations. SEARCH METHODS: We searched the Cochrane Airways Group trials register, ClinicalTrials.gov and manufacturers' websites in June 2013. SELECTION CRITERIA: Parallel, randomised controlled trials (RCTs) recruiting populations of patients with chronic obstructive pulmonary disease. Studies were required to be at least 12 weeks in duration and designed to assess the safety and efficacy of a long-acting beta2-agonist against placebo. DATA COLLECTION AND ANALYSIS: Data and characteristics were extracted independently by two review authors, and each study was assessed for potential sources of bias. Data for all outcomes were pooled and subgrouped by LABA agent (formoterol 12 μg, formoterol 24 μg and salmeterol 50 μg) and then were separately analysed by LABA agent and subgrouped by trial duration. Sensitivity analyses were conducted for the proportion of participants taking inhaled corticosteroids and for studies with high or uneven rates of attrition. MAIN RESULTS: Twenty-six RCTs met the inclusion criteria, randomly assigning 14,939 people with COPD to receive twice-daily LABA or placebo. Study duration ranged from three months to three years; the median duration was six months. Participants were more often male with moderate to severe symptoms at randomisation; mean forced expiratory volume in 1 second (FEV1) was between 33% and 55% predicted normal in the studies, and mean St George's Respiratory Questionnaire score (SGRQ) ranged from 44 to 55 when reported.Moderate-quality evidence showed that LABA treatment improved quality of life on the SGRQ (mean difference (MD) -2.32, 95% confidence interval (CI) -3.09 to -1.54; I(2) = 50%; 17 trials including 11,397 people) and reduced the number of exacerbations requiring hospitalisation (odds ratio (OR) 0.73, 95% CI 0.56 to 0.95; I(2) = 10%; seven trials including 3804 people). In absolute terms, 18 fewer people per 1000 were hospitalised as the result of an exacerbation while receiving LABA therapy over a weighted mean of 7 months (95% CI 3 to 31 fewer). Scores were also improved on the Chronic Respiratory Disease Questionnaire (CRQ), and more people receiving LABA treatment showed clinically important improvement of at least four points on the SGRQ.The number of people who had exacerbations requiring a course of oral steroids or antibiotics was also lower among those taking LABA (52 fewer per 1000 treated over 8 months; 95% CI 24 to 78 fewer, moderate quality evidence).Mortality was low, and combined findings of all studies showed that LABA therapy did not significantly affect mortality (OR 0.90, 95% CI 0.75 to 1.08; I(2) = 21%; 23 trials including 14,079 people, moderate quality evidence). LABA therapy did not affect the rate of serious adverse events (OR 0.97, 95% CI 0.83 to 1.14; I(2) = 34%, moderate quality evidence), although there was significant unexplained heterogeneity, especially between the two formoterol doses.LABA therapy improved predose FEV1 by 73 mL more than placebo (95% CI 48 to 98; I(2) = 71%, low quality evidence), and people were more likely to withdraw from placebo than from LABA therapy (OR 0.74, 95% CI 0.69 to 0.80; I(2) = 0%). Higher rates of withdrawal in the placebo arm may reduce our confidence in some results, but the disparity is more likely to reduce the magnitude of difference between LABA and placebo than inflate the true effect; removing studies at highest risk of bias on the basis of high and unbalanced attrition did not change conclusions for the primary outcomes. AUTHORS' CONCLUSIONS: Moderate-quality evidence from 26 studies showed that inhaled long-acting beta2-agonists are effective over the medium and long term for patients with moderate to severe COPD. Their use is associated with improved quality of life and reduced exacerbations, including those requiring hospitalisation. Overall, findings showed that inhaled LABAs did not significantly reduce mortality or serious adverse events